| Product Code: ETC9949764 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Neuropathic Pain Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Neuropathic Pain Market - Industry Life Cycle |
3.4 United Kingdom (UK) Neuropathic Pain Market - Porter's Five Forces |
3.5 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume Share, By Procedure, 2021 & 2031F |
3.8 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.9 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume Share, By Modality, 2021 & 2031F |
3.10 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume Share, By Mode of Purchase, 2021 & 2031F |
3.11 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume Share, By Pain Type, 2021 & 2031F |
4 United Kingdom (UK) Neuropathic Pain Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neuropathic pain in the UK due to aging population and rising cases of chronic diseases |
4.2.2 Growing awareness about neuropathic pain management and treatment options among healthcare professionals and patients |
4.2.3 Technological advancements in pain management therapies leading to better treatment outcomes |
4.3 Market Restraints |
4.3.1 High cost associated with neuropathic pain treatments and medications leading to affordability issues for patients |
4.3.2 Limited reimbursement policies for neuropathic pain treatments impacting patient access to advanced therapies |
4.3.3 Side effects and potential risks associated with neuropathic pain medications affecting patient compliance and treatment efficacy |
5 United Kingdom (UK) Neuropathic Pain Market Trends |
6 United Kingdom (UK) Neuropathic Pain Market, By Types |
6.1 United Kingdom (UK) Neuropathic Pain Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Spinal Cord Stimulation (SCS) Devices, 2021- 2031F |
6.1.4 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By External Peripheral Nerve Stimulation, 2021- 2031F |
6.1.5 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Transcutaneous Electrical Nerve Stimulation (Tens) Devices, 2021- 2031F |
6.2 United Kingdom (UK) Neuropathic Pain Market, By Product Type |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Rechargeable and Non-Rechargeable, 2021- 2031F |
6.3 United Kingdom (UK) Neuropathic Pain Market, By Procedure |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Invasive and Non-Invasive, 2021- 2031F |
6.4 United Kingdom (UK) Neuropathic Pain Market, By Technology |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Transcutaneous Electrical Nerve Stimulation, 2021- 2031F |
6.4.3 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Transcranial Magnetic Stimulation, 2021- 2031F |
6.4.4 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Respiratory Electrical Stimulation, 2021- 2031F |
6.5 United Kingdom (UK) Neuropathic Pain Market, By Modality |
6.5.1 Overview and Analysis |
6.5.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Stationary, 2021- 2031F |
6.5.3 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Portable, 2021- 2031F |
6.6 United Kingdom (UK) Neuropathic Pain Market, By Mode of Purchase |
6.6.1 Overview and Analysis |
6.6.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Over-the-Counter Devices, 2021- 2031F |
6.6.3 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Prescription-Based Devices, 2021- 2031F |
6.7 United Kingdom (UK) Neuropathic Pain Market, By Pain Type |
6.7.1 Overview and Analysis |
6.7.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Peripheral Neuropathy, 2021- 2031F |
6.7.3 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Entrapment Neuropathy, 2021- 2031F |
6.7.4 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Trigeminal Neuralgia, 2021- 2031F |
6.7.5 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Trigeminal Neuralgia, 2021- 2031F |
6.7.6 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Post Herpetic Neuralgia (PHN), 2021- 2031F |
6.7.7 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Post Traumatic Neuropathy, 2021- 2031F |
6.7.8 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Coccydynia, 2021- 2031F |
6.7.9 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Coccydynia, 2021- 2031F |
6.8 United Kingdom (UK) Neuropathic Pain Market, By Indication |
6.8.1 Overview and Analysis |
6.8.2 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Spinal Stenosis, 2021- 2031F |
6.8.3 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Chemotherapy-Induced Peripheral Neuropathy, 2021- 2031F |
6.8.4 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Others, 2021- 2031F |
6.8.5 United Kingdom (UK) Neuropathic Pain Market Revenues & Volume, By Others, 2021- 2031F |
7 United Kingdom (UK) Neuropathic Pain Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Neuropathic Pain Market Export to Major Countries |
7.2 United Kingdom (UK) Neuropathic Pain Market Imports from Major Countries |
8 United Kingdom (UK) Neuropathic Pain Market Key Performance Indicators |
8.1 Patient-reported pain relief and improvement in quality of life after treatment |
8.2 Adoption rate of non-pharmacological pain management techniques in neuropathic pain patients |
8.3 Number of clinical trials and research studies focused on developing innovative neuropathic pain treatments |
8.4 Healthcare provider satisfaction with available neuropathic pain management options |
8.5 Percentage of neuropathic pain patients receiving multidisciplinary care for holistic treatment approach |
9 United Kingdom (UK) Neuropathic Pain Market - Opportunity Assessment |
9.1 United Kingdom (UK) Neuropathic Pain Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United Kingdom (UK) Neuropathic Pain Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.3 United Kingdom (UK) Neuropathic Pain Market Opportunity Assessment, By Procedure, 2021 & 2031F |
9.4 United Kingdom (UK) Neuropathic Pain Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.5 United Kingdom (UK) Neuropathic Pain Market Opportunity Assessment, By Modality, 2021 & 2031F |
9.6 United Kingdom (UK) Neuropathic Pain Market Opportunity Assessment, By Mode of Purchase, 2021 & 2031F |
9.7 United Kingdom (UK) Neuropathic Pain Market Opportunity Assessment, By Pain Type, 2021 & 2031F |
9.7 United Kingdom (UK) Neuropathic Pain Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 United Kingdom (UK) Neuropathic Pain Market - Competitive Landscape |
10.1 United Kingdom (UK) Neuropathic Pain Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Neuropathic Pain Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here